Indian management due to culture has no clue about US markets. Its not a matter of controlling, its a matter of not understanding how to do business in the US. Some of the personnel have good experience in the US, but Opth has 1 drug in the portfolio. Low market share and sales people who really are not selling it. There were 3 anti-inflammatory NSAID that came out in 2017 alone! Prior to that Allergan and Alcon had most of the market. There are problems with NSAIDs for post surgical healing etc. Bromsite is more a "me too" drug. Unless the doc loves you, they will prescribe others. Good luck. I talked to them awhile ago when they were hiring for the Bromsite launch. They scared me away! No thank you. If youre ambitious and are driven by making money; this is not the place for you. It wasnt for me!